SHMT2 not only was found to be highly expressed in glioblastoma (GBM) (Kim et al., 2015), hepatocellular carcinoma (HCC) (Woo et al., 2016), colorectal cancer (CRC) (Wei et al., 2018), and diffuse large B-cell lymphoma (DLBCL) (Ducker et al., 2017) but also specifically promoted the growth and proliferation of tumor cells when the glycine cleavage system was not functioning properly (Kim et al., 2015). This evidence concerns the gene SHMT2 and neoplasm.